

## Special Issue

# Novel Advances in Personalized Hepatobiliary Surgery

### Message from the Guest Editors

In this Special Issue, we invite all researchers to contribute relevant clinical or basic studies regarding hepatobiliary primitive or secondary tumors (hepatocarcinoma, cholangiocarcinoma, colorectal liver metastasis, neuroendocrine liver metastasis, and non-colorectal, non-neuroendocrine liver metastasis) focused on integrated therapy of these malignancies, the use of prognostic molecular biomarkers, new therapeutic indications, new treatment frontiers, borderline therapeutic choices in complex cases, treatment of complex recurrences, and modern application of molecular biomarkers. Original and review articles (systematic and narrative approaches) are also welcome. Papers that meet the criteria of the peer review process will be accepted for publication. We hope that this Special Issue will enrich our knowledge of hepatobiliary tumors and further select the right patients to receive optimal management to improve the quality and outcomes of cancer patient care in surgery.

### Guest Editors

Dr. Edoardo Maria Muttillio

Prof. Dr. Fabrizio Panaro

Dr. Fabio Giannone

### Deadline for manuscript submissions

closed (10 April 2025)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/212207](https://mdpi.com/si/212207)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).